National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Dictionary of Cancer Terms
Send to Printer
IDEC-Y2B8

 A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. IDEC-Y2B8 is a type of radiopharmaceutical. Also called yttrium Y 90 ibritumomab tiuxetan, Y 90 ibritumomab tiuxetan, and Y 90 Zevalin.

Previous Definitions:ibuprofen, ICD, ICI 182780, ICI D1694, idarubicin
Next Definitions:idiopathic, idiopathic myelofibrosis, idiopathic pneumonia syndrome, idiopathic thrombocytopenic purpura, idoxifene